Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns
Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns Global finance never sleeps. […]
